Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $496.3 million.

  • Krystal Biotech's Cash & Equivalents rose 4391.25% to $496.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $496.3 million, marking a year-over-year increase of 4391.25%. This contributed to the annual value of $496.3 million for FY2025, which is 4391.25% up from last year.
  • Krystal Biotech's Cash & Equivalents amounted to $496.3 million in Q4 2025, which was up 4391.25% from $392.6 million recorded in Q3 2025.
  • Krystal Biotech's Cash & Equivalents' 5-year high stood at $496.3 million during Q4 2025, with a 5-year trough of $140.7 million in Q1 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $343.1 million (2021), whereas its average is $316.0 million.
  • In the last 5 years, Krystal Biotech's Cash & Equivalents tumbled by 5255.62% in 2022 and then skyrocketed by 15507.55% in 2024.
  • Over the past 5 years, Krystal Biotech's Cash & Equivalents (Quarter) stood at $341.2 million in 2021, then crashed by 52.56% to $161.9 million in 2022, then skyrocketed by 121.33% to $358.3 million in 2023, then dropped by 3.76% to $344.9 million in 2024, then soared by 43.91% to $496.3 million in 2025.
  • Its Cash & Equivalents was $496.3 million in Q4 2025, compared to $392.6 million in Q3 2025 and $353.8 million in Q2 2025.